NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017

View More View Less
  • 1 From Fox Chase Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Huntsman Cancer Institute at the University of Utah; University of Alabama at Birmingham Comprehensive Cancer Center; FORCE: Facing Our Risk of Cancer Empowered; Dana-Farber/Brigham and Women's Cancer Center; Duke Cancer Institute; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; University of Colorado Cancer Center; Stanford Cancer Institute; The University of Texas MD Anderson Cancer Center; UC San Diego Moores Cancer Center; University of Michigan Comprehensive Cancer Center; Memorial Sloan Kettering Cancer Center;Moffitt Cancer Center; Fred & Pamela Buffett Cancer Center;Massachusetts General Hospital Cancer Center; University of Washington Medical Center/Seattle Cancer Care Alliance; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Roswell Park Cancer Institute; City of Hope Comprehensive Cancer Center; Mayo Clinic Cancer Center; Vanderbilt-Ingram Cancer Center; and National Comprehensive Cancer Network.
Restricted access

The NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling for hereditary cancer syndromes and risk management recommendations for patients who are diagnosed with a syndrome. Guidelines focus on syndromes associated with an increased risk of breast and/or ovarian cancer. The NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. The NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding risk management for carriers of moderately penetrant genetic mutations associated with breast and/or ovarian cancer.

Provided content development and/or authorship assistance.

Supplementary Materials

    • Supplemental Material (PDF 228 KB)
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 5292 3593 198
PDF Downloads 1459 1074 138
EPUB Downloads 0 0 0